The designation recognizes BRIJ-SEAL for its potential to enhance patient safety and clinical outcomes. Unlike traditional cyanoacrylate-based adhesives, the device features a proprietary hypoallergenic formula designed to minimize skin reactions. It functions as a sterile, waterproof barrier that remains effective for 14 days while allowing the incision site to breathe.

CEO Tim Gleeson stated that the inclusion of BRIJ-SEAL completes a comprehensive portfolio of incision management tools. The company’s broader clinical data, which includes a randomized controlled trial at UT Southwestern, indicates that its incision management platform can reduce wound breakdown by 90% and scar area by 38%. Surgeons may now utilize BRIJ-SEAL independently or in tandem with the Brijjit BP-100 and BP-75 systems to combine tension offloading with protective sealing.